Global Metastatic Cancer Drug Market, Dosage, Price and Clinical Pipeline Outlook 2024

Download Sample

For Report Sample Contact: neeraj@kuickresearch.com

Report Weblink: https://www.kuickresearch.com/report-global-metastatic-cancer-drug-market,-dosage,-price-and-clinical-pipeline-outlook-2024.php

Table of Contents

1. Cancer Metastasis: New Perspectives of Old Problem
1.1 Overview to Cancer
1.1.1 Process of Metastatic Cancer
1.1.2 Risk Factors Involved for the Metastasis of Cancer
1.2 Genes Involved in Metastasis of Cancer

2. Metastatic Lung Cancer
2.1 Introduction
2.2 Management Approaches for Metastatic Lung Cancer
2.3 Advancements in the Treatment of Metastatic Lung Cancer

3. Metastatic Bone Cancer
3.1 Introduction
3.2 Management Approaches of Metastatic Bone Cancer

4. Metastatic Breast Cancer
4.1 Overview
4.2 Management Methods for Metastatic Breast Cancer
4.3 Ongoing Advancements in Metastatic Breast Cancer Treatment

5. Metastatic Liver Cancer
5.1 Introduction
5.2 Management Approaches of Metastatic Liver Cancer

6. Metastatic Brain Cancer
6.1 Outline
6.2 Management Methods for Metastatic Brain Tumor
6.3 Developments in Metastatic Brain Tumors

7. Metastatic Prostate Cancer
7.1 Introduction
7.2 Management of Metastatic Prostate Cancer
7.3 Recent Advances in Metastatic Prostate Cancer Treatment

8. Process of Metastasis in Other Different Types of Cancers
8.1 Ovarian Cancer
8.2 Thyroid Cancer
8.3 Pancreatic Cancer

9. Patent, Availability, Price and Dosage Analysis of Metastatic Lung Cancer Therapeutics
9.1 Targeted Drugs
9.1.1 Erlotinib (Tarceva)
9.1.2 Gefitinib (Iressa)
9.1.3 Afatinib (Gilotrif)
9.2 Chemotherapy Drugs
9.2.1 Cisplatin
9.2.2 Topotecan (Hycamtin)
9.2.3 Pemetrexed (Alimta)

10. Patent, Availability, Price and Dosage Analysis of Metastatic Bone Cancer Therapeutics
10.1 Denosumab
10.2 Radium 223
10.3 Zoledronic acid

11. Patent, Availability, Price and Dosage Analysis of Metastatic Breast Cancer Therapeutics
11.1 Chemotherapy Drugs
11.1.1 Capecitabine
11.1.2 Eribulin (Halaven)
11.1.3 Ixabepilone (Ixempra)
11.2 Targeted Therapy Drugs
11.2.1 Avastin (Bevacizumab)
11.2.2 Herceptin

12. Patent, Availability, Price and Dosage Analysis of Metastatic Liver Cancer Therapeutics
12.1 Sorafenib (Nexavar)
12.2 Melphalan (Alkeran)

13. Patent, Availability, Price and Dosage Analysis of Metastatic Prostate Cancer Therapeutics
13.1 Taxotere (Docetaxel)
13.2 Jevtana (Cabazitaxel)
13.3 Provenge (Sipuleucel-T)

14. Market Analysis of Metastatic Cancer
14.1 Current Market Growth of Metastatic Cancer by its Types
14.2 Global Sales of Metastatic Cancers Drugs

15. Market Dynamics of Metastatic Cancer
15.1 Favorable Parameters
15.2 Challenges

16. Future Perspective of Metastatic Cancer Market

17. Global Cancer Metastases Clinical Pipeline Overview

18. Global Cancer Metastases Clinical Pipeline by Company, Indication and Phase
18.1 Research
18.2 Preclinical
18.3 Clinical
18.4 Phase-0
18.5 Phase-I
18.6 Phase-I/II
18.7 Phase-II
18.8 Phase-III
18.9 Preregistration

19. Marketed Cancer Metastases Drugs Clinical Insight
19.1 Denosumab (PRALIA, Prolia, Ranmark and Xgeva)
19.2 Radium-223 Chloride (Alpharadin and Xofigo)
19.3 Zoledronic Acid (Aclasta, Reclast and Zometa)
19.4 Pamidronic Acid (Aminomux, Aredia and Panorin)
19.5 Clodronic Acid (Ascredar, Bonefos, Bonephos, Clasteon, Clastoban, Climaclod, Clodeosten, Clodron, Clodron beta, Clody, Difosfonal, Dolkin, Hemocalcin, Lodronat, Loron, Lytos, Mebonat, Moticlod, Nikclod, Ossiten, Ostac, Osteonorm, Osteostab and Sindronat)
19.6 Ibandronic Acid (Bondronat, Boniva and Bonviva)
19.7 Thiotepa (Tepadina and Thioplex)
19.8 Miltefosine (Impavido, Miltefosin and Miltex)
19.9 Irinotecan-Eluting Beads (DEBIRI and PARAGON Bead)
19.10 Melphalan Drug Delivery System (Delcath Hepatic CHEMOSAT Delivery System for Melphalan and Melblez Kit)
19.11 Ethiodised Oil (Lipiodol)
19.12 Zoledronic Acid - Sagent Pharmaceuticals
19.13 Tc 99m Besilesomab (Scintimun)
19.14 Mopidamol (Rapenton)

20. Competitive Landscape
20.1 Allergan
20.2 Amgen
20.3 Biocompatibles International
20.4 Boehringer Ingelheim Pharma
20.5 Celsion Corporation
20.6 DexTech Medical
20.7 Immune Pharmaceuticals
20.8 GlaxoSmithKline
20.9 Hospira
20.10 Insmed
20.11 Novartis
20.12 Pfizer
20.13 Roche

Figure 1-1: Reasons for the Development of Cancer Cases (%)
Figure 1-2: Process Involved in the Metastasis of Cancer
Figure 1-3: Classes of Genes Participating in Metastatic Process in Cancer
Figure 2-1: Diagnostic Methods for Metastatic Lung Cancer
Figure 3-1: Diagnostic Approaches for Metastatic Bone Cancer
Figure 4-1: Metastatic Breast Cancer Diagnostic Methods
Figure 5-1: Metastatic Liver Cancer Diagnostic Methods
Figure 5-2: Treatment Approaches for Metastatic Liver Cancer
Figure 6-1: Diagnostic Approaches to Brain Tumor
Figure 6-2: Treatment Methods for Metastatic Brain Tumor
Figure 7-1: Diagnostic Approaches for Metastatic Prostate Cancer
Figure 7-2: Treatment Methods for Metastatic Prostate Cancer
Figure 9-1: Tarceva andndash; Patent Approval and Expiration Year for Advance Stage Lung Cancer
Figure 9-2: Tarceva andndash; Available Concentrations (mg), 2018
Figure 9-3: Tarceva andndash; Dosage Analysis and Dose Modifications (mg/Day), 2018
Figure 9-4: Tarceva andndash; Increased Dosage by Condition (mg/Day), 2018
Figure 9-5: Tarceva andndash; Price Analysis by Concentration (US$), 2018
Figure 9-6: Tarceva andndash; Therapy Cost Analysis (US$/Patient), 2018
Figure 9-7: Gefitinib andndash; Drug Patent Approval Year and Expiration Year for Lung Cancer
Figure 9-8: Gefitinib andndash; Clinical Efficacy by Patients Undergoing Treatment (%), 2018
Figure 9-9: Gefitinib andndash; Dosage Analysis (mg), 2018
Figure 9-10: Gefitinib andndash; Available Concentrations (mg), 2018
Figure 9-11: Gefitinib andndash; Therapy Cost Analysis (US$/Patient), 2018
Figure 9-12: Afatinib andndash; Patent Approval and Expiration Year for the Treatment of Lung Cancer
Figure 9-13: Afatinib - Available Concentrations (mg), 2018
Figure 9-14: Afatinib andndash; Therapy Cost Analysis (US$), 2018
Figure 9-15 Cisplatin andndash; Available Concentrations (ml), 2018
Figure 9-16: Cisplatin andndash; Price Analysis by Concentration (US$), 2018
Figure 9-17: Topotecan - Patent Approval and Expiration Year
Figure 9-18: Topotecan andndash; Available Concentration by Form (mg), 2018
Figure 9-19: Topotecan andndash; Dosage Analysis by Route of Administration (mg/m2/Dose), 2018
Figure 9-20: Topotecan andndash; Treatment Cycle Analysis (Number of Days), 2018
Figure 9-21: Topotecan andndash; Dosage Analysis by Route of Administration (mg/Cycle), 2018
Figure 9-22: Topotecan andndash; Capsule Price Analysis by Concentration (US$/Unit), 2018
Figure 9-23: Topotecan andndash; Price Analysis by Drug Form (US$/Packet), 2018
Figure 9-24: Alimta Patent Approval and Expiration Year for Advanced Lung Cancer Treatment
Figure 9-25: Alimta - Available Concentration (mg), 2018
Figure 9-26: Alimta andndash; Dosage Analysis (mg/Day), 2018
Figure 9-27: Alimta andndash; Price Analysis by Concentration (US$), 2018
Figure 10-1: Patent Approval and Expiry Year of Denosumab Drug
Figure 10-2: Denosumab - Available Concentration and Dosage Analysis by Brand (mg/Day), 2018
Figure 10-3: Denosumab Comparative Cost Analysis andndash; Xgeva v/s Prolia (US$/Unit)
Figure 10-4: Xofigo Patent Approval and Expiry Year
Figure 10-5: Xofigo andndash; Therapy Cost Analysis (US$), 2018
Figure 10-6: Patent Approval Year and Expiry Year
Figure 10-7: Zometa andndash; Available Concentrations (mg/ml), 2018
Figure 10-8: Zometa - Dosage and Treatment Cycle Duration Analysis (mg/Cycle), 2018
Figure 10-9: Zometa andndash; Price Analysis (US$/Vial), 2018
Figure 11-1: Capecitabine - Available Concentrations (mg), 2018
Figure 11-2: Capecitabine andndash; Dosage Analysis (mg/m2/Day), 2018
Figure 11-3: Capecitabine andndash; Treatment Cycle Duration Analysis (Number of Weeks), 2018
Figure 11-4: Capecitabine and Xeloda - Comparative Cost Analysis by Concentration (US$/Packet), 2018
Figure 11-5: Eribulin Drug Patent Approval Year and Expiration Year for Metastatic Breast Cancer
Figure 11-6: Eribulin andndash; Availability and Dosage Analysis (mg), 2018
Figure 11-7: Eribulin andndash; Price Analysis (US$), 2018
Figure 11-8: Eribulin andndash; Clinical Efficacy Based on Clinical Trial Results (%), 2018
Figure 11-9: Ixabepilone Patent Approval and Expiry Year for Breast Cancer Treatment
Figure 11-10: Ixempra - Available Concentrations (MG), 2018
Figure 11-11: Ixempra andndash; Dosage Analysis (mg/m2/Day), 2018
Figure 11-12: Ixempra andndash; Price Analysis by Concentration (US$), 2018
Figure 11-13: Avastin Patent Approval and Expiration Year
Figure 11-14: Avastin andndash; Available Concentrations (ml), 2018
Figure 11-15: Avastin andndash; Average Dosage Analysis (mg/kg), 2018
Figure 11-16: Avastin andndash; Price Analysis (US$), 2018
Figure 11-17: Avastin andndash; Clinical Efficacy Based on Clinical Trial Results (%), 2018
Figure 11-18: Herceptin - Available Concentrations (mg), 2018
Figure 11-19: Herceptin andndash; Dosage Analysis (mg/kg), 2018
Figure 11-20: Herceptin andndash; Price Analysis by Concentration (US$), 2018
Figure 12-1: Nexavar - Patent Approval and Expiry Year
Figure 12-2: Nexavar andndash; Availability and Dosage Analysis (mg), 2018
Figure 12-3: Nexavar - Price Analysis (US$), 2018
Figure 12-4: Nexavar andndash; Therapy Cost Analysis (US$/Patient), 2018
Figure 12-5: Alkeran - Drug Patent Approval and Expiration Year
Figure 12-6: Alkeran andndash; Available Concentrations by Drug Form (mg), 2018
Figure 12-7: Alkeran andndash; Treatment Cycle Analysis (By Number), 2018
Figure 12-8: Alkeran andndash; Price Analysis by Drug Form (US$), 2018
Figure 13-1: Docetaxel - Available Concentrations (mg/ml), 2018
Figure 13-2: Docetaxel andndash; Dosage Analysis (mg/m2/Dose), 2018
Figure 13-3: Docetaxel andndash; Price Analysis (US$/Unit), 2018
Figure 13-4: Jevtana - Patent Approval and Expiry Year for Metastatic Prostate Cancer Treatment
Figure 13-5: Jevtana andndash; Available Concentration and Dosage Analysis (mg), 2018
Figure 13-6: Jevtana andndash; Price Analysis (US$), 2018
Figure 13-7: Patent Approval Years of Provenge Drug in US and Europe
Figure 13-8: Provenge andndash; Number of Autologous CD54+ Activated Cells (Million)
Figure 13-9: Provenge andndash; Dosage Administration (Minutes)
Figure 13-10: Provenge - Average Duration of Therapy
Figure 13-11: Provenge - Cost of Intravenous Solution and per Unit Cost, US$
Figure 13-12: Provenge - Therapy Cost Analysis (US$/Infusion), 2018
Figure 13-13: Provenge andndash; Average Cost (US$/Patient), 2018
Figure 13-14: Provenge andndash; Therapy Cost Analysis (US$/Treatment Course), 2018
Figure 13-15: Overall Survival Rate among the Patients Using Provenge Drug (%)
Figure 14-1: Global andndash; Metastatic Cancer Therapy Market Forecast (US$ Billion), 2017-2027
Figure 14-2: Global andndash; Breast Cancer Therapeutics Forecast (US$ Billion), 2016-2026
Figure 14-3: Global - Prostate Cancer Therapeutics Market Forecast (US$ Billion), 2016-2027
Figure 14-4: Global andndash; Tarceva Sales (US$ Million), 2015 andndash; 2017
Figure 14-5: Global andndash; Iressa Sales Analysis (US$ Million), 2015 - 2017
Figure 14-6: Global - Hycamtin Sales Analysis (US$ Million), 2015 and 2016
Figure 14-7: Global - Alimta Sales Analysis (US$ Million), 2015 andndash; 2017*
Figure 14-8: Global - Prolia Sales Analysis (US$ Million), 2015 andndash; 2017*
Figure 14-9: Global - Xofigo Sales Analysis (US$ Million), 2015 and 2017*
Figure 14-10: Global - Eribulin Sales Analysis (US$ Million), 2015 and 2016
Figure 14-11: Global - Avastin Sales Analysis (US$ Billion), 2015 andndash; 2017*
Figure 14-12: Global andndash; Herceptin Sales Analysis (US$ Billion), 2015 andndash; 2017*
Figure 14-13: Global - Nexavar Sales Analysis (US$ Million), 2015 andndash; 2017*
Figure 14-14: Global - Jevtana Sales Analysis (US$ Million), 2015 andndash; 2017*
Figure 14-15: Global - Provenge Sales Analysis (US$ Million), 2015 and 2016
Figure 15-1: Favorable Parameters to Metastatic Cancer Market Growth
Figure 15-2: Challenges for the Development of Metastatic Cancer Treatment
Figure 17-1: Global Cancer Metastases Pipeline by Phase (%), 2018 till 2024
Figure 17-2: Global Cancer Metastases Pipeline by Phase (Number), 2018 till 2024
Figure 17-3: Global Cancer Metastases Pipeline by Phase (%), 2018 till 2024
Figure 17-4: Global Cancer Metastases Pipeline by Phase (Number), 2018 till 2024






Table 3-1: Role of Tumor Secreted Factors in Establishment of Osteolytic and Osteoblastic Metastasis
Table 4-1: Organ Specific Breast Cancer Metastasis Progression and Virulence
Table 6-1: Modern Challenges and Solutions in Management of Brain Metastasis
Table 9-1: Patients Benefited by Using Afatinib Drug for Metastatic Lung Cancer
Table 9-2: Formulation and Preparation of Topotecan Drug, mg
Table 11-1: Clinical Efficacy of Using Eribulin for Metastatic Breast Cancer Treatment
Table 11-2: Clinical Efficacy of Using Ixempra for Metastatic Breast Cancer Treatment
Table 11-3: Clinical Efficacy Result of Avastin Drug with Paclitaxel drug
Table 11-4: Clinical Efficacy for the use of Herceptin Combined with Paclitaxel or Docetaxel

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.